Last reviewed · How we verify
NCT06915272: MS Sailing
Effects of Sailing and Cooing in the Quality of Life of Multiple Sclerosis Individuals
NA trial testing Head and Neck Cooling Intervention in Multiple Sclerosis (MS) - Relapsing-remitting in 45 participants. Completed in 17 May 2023.
15 May 2023
Quick facts
| Lead sponsor | University of Thessaly |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 45 |
| Start date | 6 May 2023 |
| Primary completion | 15 May 2023 |
| Estimated completion | 17 May 2023 |
| Sites | 1 location across Greece |
Drugs / interventions tested
- Head and Neck Cooling Intervention
Conditions studied
- Multiple Sclerosis (MS) - Relapsing-remitting — all drugs for Multiple Sclerosis (MS) - Relapsing-remitting →
Sponsor
University of Thessaly
Who can join
Eligibility, any sex, with Multiple Sclerosis (MS) - Relapsing-remitting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, we aim to evaluate the impact of head and neck cooling on symptoms and psychological states in individuals with Multiple Sclerosis (MS) during a 7-day Oceans of Hope Challenge sailing trip around the Greek islands of the Argosaronic Gulf in May 2023. Forty-five individuals with relapsing-remitting MS will participate in the sailing trip. Participants will be allocated to either a Cooling group (n=25), using a cooling cap and neck towel for at least two hours per day, or a Control group (n=20) without cooling interventions. Before and after the trip, participants will complete the Functional Assessment of Multiple Sclerosis Scale (FAMS), the Environmental Symptoms Questionnaire (ESQ), and the abbreviated 40-item Profile of Mood States (POMS-40). These assessments will be used to evaluate quality of life, environmental symptoms, and mood states. The study is designed to examine whether daily use of head and neck cooling during a prolonged outdoor activity influences MS-related symptoms, quality of life, and psychological well-being.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06915272
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple Sclerosis (MS) - Relapsing-remitting
Currently open trials in the same condition.
- NCT07376772 — Wearable Focal Vibration Therapy on Upper Extremity Function of People With Multiple Sclerosis: A Pilot Study · NA · recruiting
- NCT07225361 — Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis · Phase 4 · recruiting
- NCT07355387 — Home Based Functional Balance Intervention for Multiple Sclerosis · NA · recruiting
- NCT06629428 — Effects of Ublituximab on Motor Functions in Multiple Sclerosis · EARLY_PHASE1 · recruiting
- NCT07222618 — "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS · recruiting
Other University of Thessaly trials
Trials by the same sponsor.
- NCT07376187 — Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases · NA · not yet recruiting
- NCT07496151 — The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. · NA · not yet recruiting
- NCT07420309 — Colonoscopy TRaining With or Without Artificial INtelligence Among Endoscopy Residents · NA · recruiting
- NCT07341711 — Long-term Adaptations of Skeletal Muscle After Hybrid Training. · NA · not yet recruiting
- NCT07380009 — Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx® 460 Neo 9 in Adults Rece · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06915272 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Thessaly
- Last refreshed: 8 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06915272.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing